ImmunityBio, Inc. (IBRX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$15.5M
Cash & Equivalents
$75.4M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$8,609M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-31 | Phase2 Readout | — |
| 2026-09-30 | Phase2 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
| 2027-05-01 | Phase2 Readout | — |
| 2027-05-25 | Phase2 Readout | — |
| 2027-06-01 | Phase1 Readout | — |
Active Clinical Trials (18)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05981131 | Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) | OTHER | Active Not Recruiting | 6 |
| NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Mon... | PHASE3 | Recruiting | 507 |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-... | PHASE3 | Active Not Recruiting | 190 |
| NCT02782546 | Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | PHASE2 | Active Not Recruiting | 60 |
| NCT02138734 | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | PHASE2 | Active Not Recruiting | 369 |
| NCT07125872 | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | PHASE2 | Recruiting | 20 |
| NCT07123727 | A Study to Examine Anktiva for the Treatment of COVID-19. | PHASE2 | Recruiting | 40 |
| NCT06710288 | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Com... | PHASE2 | Recruiting | 20 |
| NCT04390399 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of L... | PHASE2 | Active Not Recruiting | 328 |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesic... | PHASE2 | Recruiting | 40 |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Check... | PHASE2 | Active Not Recruiting | 40 |
| NCT07108036 | A Study to Assess Anktiva in Patients With Long Covid-19. | PHASE2 | Recruiting | 20 |
| NCT06239220 | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | PHASE2 | Recruiting | 25 |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | PHASE2 | Active Not Recruiting | 34 |
| NCT04898543 | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | PHASE1 | Active Not Recruiting | 50 |
| NCT04340596 | Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antib... | PHASE1 | Active Not Recruiting | 118 |
| NCT06334991 | Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | PHASE1 | Active Not Recruiting | 20 |
| NCT05976828 | IBRX-042 In Participants With HPV-Associated Tumors | PHASE1 | Active Not Recruiting | 12 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.